MEDICINE DETAILS
Danyelza
Active ingredient: Naxitamab Gqgk
Neutral reference profile for an independent medicine-access consultancy enquiry about Danyelza (Naxitamab Gqgk). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
No ready-made options were found for this medicine. You can type the details in the form.
Continue to the form→✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Danyelza used for?
Danyelza (naxitamab-gqgk) is a GD2-binding monoclonal antibody (immunotherapy) indicated for the treatment of adults and children aged 1 year and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
It is indicated for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for patients who have achieved partial or minor response or stable disease with prior treatment.
It is available in injection form containing 40 mg/10 mL naxitamab-gqgk per vial.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Danyelza identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
No ready-made option can be shown.
Do not guess a missing strength or pack; use the details on the prescription and medicine box.
OFFICIAL SOURCES
Check the Danyelza record at an official source.
Search for “Danyelza” or “Naxitamab Gqgk”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Danyelza.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Danyelza
01What is Danyelza?＋
This directory record associates the brand name Danyelza with the active ingredient Naxitamab Gqgk. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Danyelza strengths and packs are recorded?＋
No ready-made strength and pack option can currently be shown from the catalogue record. Do not guess missing details; use the prescription and medicine box.
03Who manufactures Danyelza?＋
No organisation name can currently be shown confidently from the catalogue record. Verify the manufacturer or marketing-authorisation holder on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Danyelza?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Danyelza, payment request, stock guarantee or binding offer.
06Can I buy Danyelza from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.